P146 A Multicentre Retrospective Study Evaluating the Real-World Efficacy and Safety of Ritlecitinib in the Treatment of Alopecia Areata

This multicentre retrospective study evaluated the real-world efficacy and safety of ritlecitinib in treating alopecia areata (AA) in 31 patients, with an average age of 36 years and a female-to-male ratio of 4:1. After 52 weeks of treatment, 51% of patients achieved a Severity of Alopecia Tool (SALT) score of ≤ 20, indicating significant hair regrowth, although the response was slow, with only 8 patients showing benefits by week 16. The study found no serious adverse events, though 2 patients experienced treatment interruptions due to transient blood abnormalities or infection. These findings suggest that ritlecitinib is a promising treatment for AA, with international registries needed to further explore predictors of response and treatment duration.